Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer
Source:   Release Date: 2022-06-01

SHANGHAI and SAN DIEGO, Jun. 1, 2022 –Neurophth Therapeutics, Inc., (hereinafter referred to as “Neurophth”) today announced the appointment of Xiaoning Guo, Ph.D., as the Chief Medical Officer (CMO). Dr. Xiaoning Guo will have overall responsibility for the drug development function, including clinical development, medical, and pipeline management.

Dr. Guo has over 20 years of experiences in drug discovery and development in the healthcare industry, including 10 years' clinical development and portfolio management experiences in R&D in multinational pharmaceutical companies and global CRO. He joins Neurophth from SciClone Pharmaceuticals, where he served as Head of R&D and Chief Medical Officer, leading the development of several drugs and clinical work. Prior to joining SciClone Pharmaceuticals, he was the  deputy general manager, the head of clinical development and regulatory affairs at General Regeneratives (Shanghai) Limited. He held key leadership positions in drug discovery and development at AstraZeneca, Johnson & Johnson, Covance, leading multiple global R&D projects.

Dr. Guo received his PhD in Pharmacology from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and his BSc in Chemistry from Nanjing University. He is also a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Chinese Society of Clinical Oncology (CSCO) and Chinese Pharmacological Society (CPS).

“I’m delighted to welcome Dr. Guo on behalf of the whole company.” said Prof. Bin Li, Founder, Chairman and CEO at Neurophth, “The IND application of our core product NR082 has been approved by both NMPA and FDA, and we poised to carry out phase III clinical trial in China and phase I in US. At this critical juncture, Dr. Guo will make a great addition to Neurophth team, bringing his profound global clinical experiences, deep medical expertise, and outstanding leadership. We look forward to his partnership in enhancing our capabilities and efficiency in clinical development, optimizing our pipeline strategy, and staging the new initiatives in our strategic development.”

Dr. Guo, Chief Medical Officer suggested that “Neurophth has been in the forefront of gene therapy for ocular disease. I shared the same vision of making meaningful changes through innovative gene therapy and I’m looking forward to joining the endeavor with the whole team in accelerating the global clinical development of gene therapy, delivering on our commitment, and contributing to our goal of becoming the world’s leading gene therapy company.”